Viamet Pharmaceuticals Holdings LLC pulled its plans for an initial public offering, according to a filing with the Securities and Exchange Commission late Friday. In a statement, Viamet said it “has determined not to pursue at this time” an IPO, nor has it sold any securities. The biotech company initially filed for an IPO in April, and in May said it was pricing 5.7 million shares at $14 to $16 apiece.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News